Allogene Therapeutics (ALLO) Total Non-Current Liabilities (2018 - 2026)

Allogene Therapeutics has reported Total Non-Current Liabilities for 9 years, with the latest figure at $101.0 million in Q1 2026.

• Quarterly Total Non-Current Liabilities fell 9.3% year-over-year to $101.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $101.0 million (down 9.3% YoY) and the FY2025 annual result came in at $107.6 million, down 9.44% from the prior year.
• Total Non-Current Liabilities fell to $101.0 million in Q1 2026 per ALLO's latest filing, from $107.6 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $152.9 million in Q1 2023 and troughed at $101.0 million in Q1 2026.
• A 5-year average of $124.4 million and a median of $119.8 million in 2024 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2022 and 2024: Total Non-Current Liabilities jumped 46.5% in 2022, then dropped 21.65% in 2024.
• Over 5 years, Total Non-Current Liabilities stood at $148.8 million in 2022, then slipped by 15.74% to $125.4 million in 2023, then decreased by 5.31% to $118.8 million in 2024, then retreated by 9.44% to $107.6 million in 2025, then fell by 6.13% to $101.0 million in 2026.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $101.0 million, $107.6 million, and $109.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.